About Intezyne
Intezyne is a company based in Tampa (United States) founded in 2004.. Intezyne has raised $19.32 million across 7 funding rounds from investors including NIH, HHS and European Patent Office. The company has 4 employees as of December 31, 2022. Intezyne has completed 1 acquisition, including Niiki Pharma. Intezyne offers products and services including Cancer Therapies. Intezyne operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Tampa, United States
- Employees 4 as on 31 Dec, 2022
-
Sectors
TechnologyHealthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Intezyne Technologies, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$19.32 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series A
Oct 06, 2017
-
Investors
NIH
& 3 more
-
Employee Count
4
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intezyne
Intezyne offers a comprehensive portfolio of products and services, including Cancer Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops innovative treatments targeting cancer through research
Funding Insights of Intezyne
Intezyne has successfully raised a total of $19.32M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series A — $10.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2017 | Amount | Series A - Intezyne | Valuation | Gaston Capital |
|
| Jun, 2016 | Amount | Series A - Intezyne | Valuation |
investors |
|
| Sep, 2013 | Amount | Grant - Intezyne | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Intezyne
Intezyne has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and European Patent Office. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Gaston Capital is engaged in growth equity investments in U.S. companies.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Intezyne
Intezyne has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Niiki Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oncology company specializing in cancer treatments
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Intezyne
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intezyne Comparisons
Competitors of Intezyne
Intezyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Intezyne
Frequently Asked Questions about Intezyne
When was Intezyne founded?
Intezyne was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Where is Intezyne located?
Intezyne is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Is Intezyne a funded company?
Intezyne is a funded company, having raised a total of $19.32M across 7 funding rounds to date. The company's 1st funding round was a Grant of $139.59K, raised on Apr 22, 2010.
How many employees does Intezyne have?
As of Dec 31, 2022, the latest employee count at Intezyne is 4.
What does Intezyne do?
Intezyne Technologies develops drugs for the treatment of various tumor diseases. It develops IVECT Method, a nanotechnology platform to target the chemotherapeutics anti-tumor activity directly within the tumor. IVECT Method can deliver many classes of small molecules, in addition to nucleic acids, oligopeptides, and diagnostic imaging agents. The companys product portfolio contains two types of products, Drugs targeting pathways in the endoplasmic reticulum of the cancer cell (IT-139, IT-235) and Drugs based on the Companys IVECT nanoparticle platform (IT-141, IT-143,IT-147). In 2013, Intezyne acquired Niiki Pharma, an oncology company specializing in cancer treatments.
Who are the top competitors of Intezyne?
Intezyne's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Intezyne offer?
Intezyne offers Cancer Therapies.
How many acquisitions has Intezyne made?
Intezyne has made 1 acquisition, including Niiki Pharma.
Who are Intezyne's investors?
Intezyne has 4 investors. Key investors include NIH, HHS, European Patent Office, and Gaston Capital.